|Bid||7.20 x 0|
|Ask||7.30 x 0|
|Day's range||7.20 - 7.50|
|52-week range||0.06 - 9.18|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Admedus Limited (ASX:AHZ), announced today that it has changed the Company’s name to Anteris Technologies Ltd (“Anteris”). As of May 22, 2020 Anteris, is trading on the Australian Securities Exchange under the ticker AVR. This milestone signifies the completion of Admedus’ restructuring program focused on transitioning to a dedicated structural heart company anchored by ADAPT®, a next generation regenerative bioscaffold platform technology being utilized to address multiple cardiovascular procedures and repairs including, a product (DurAVR™) in development for Transfemoral Aortic Valve Replacement (TAVR) procedures.
When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right...
The acquired patches, marketed under the brands CardioCel® and VascuCel®, are processed in a manner that is intended to reduce the risk of calcification. Annualized 2019 sales of these product lines were $7.1 million, mostly in the US and Europe. Guidance on how this acquisition may affect LeMaitre Vascular’s 2019 revenue, operating income and EPS expectations will be provided at the Company’s Q3 2019 earnings call on October 23, 2019.